The Competition Board imposed fines on pharmaceutical manufacturers Novartis and Roche for trying to push a more expensive medicine used for eye diseases over a cheaper one. The decision was taken unanimously, according to the statement from the Competition Board. As a result of the investigation carried out within the scope of Article 4 of the Competition Law, Novartis and Roche were issued administrative fines of TRY 165.4m and TRY 112.9m, respectively. The companies have the right to appeal the decision in the Ankara Administrative Courts within 60 days.
Latest News:
The message from Russia: ‘I am in the Middle East too’
What matters on Thursday, March 23
The post-earthquake needs analysis
What matters on Wednesday, March 22
World automotive sector influenced by semiconductors (chip sector) demand
The highest monthly CAD in the history of the republic
What matters on Tuesday, March 21
What matters on Monday, March 20
Dollar lost its savings instrument edge
Quake-hit cities to get investment support
15% of earthquake victim voters migrated
What matters on Tuesday, March 14
A law specific to Istanbul is a must: Mayor of Istanbul
Share of compensation of employees in the GVA hits a 25-year low
Hunger limit doesn’t fit in wallets; new banknote is needed
Opposition bloc eyes deal to reunite, elevate popular mayors
Central Bank and SFD ink USD 5bn deposit deal
What matters on Monday, March 6
A big slowdown in the rate of interest reduction!
Turkey at a Glance
COMPETITION WATCHDOG FINES NOVARTIS AND ROCHE TRY 278M
February 1, 2021March 15, 2021

Leave a Reply